Key result
SIN-1 had no influence on ischemic parameters in ECG, hemodynamics, or angina severity compared to placebo, showing no direct myocardial anti-ischemic response.
Why the study?
Does SIN-1 improve ischemic parameters in patients when administered via intracoronary or intravenous routes?
RCT (n=21)
Double-blind
randomized
Does SIN-1 improve ischemic parameters in patients when administered via intracoronary or intravenous routes?
Low-dose SIN-1 administered intravenously or intracoronarily does not exert direct myocardial anti-ischemic effects, indicating its clinical efficacy relies on peripheral and vascular mechanisms.
Answers are grounded in this paper and cite their sources.
No direct myocardial anti-ischemic effect from low-dose SIN-1; confirms peripheral vascular mediation and directs trials to vascular endpoints.
Anti-ischemic drugs may develop their cardiac activity via peripheral (reduction in preload and/or afterload) or cardiac (coronary vasculature, myocardial cell metabolism) effects. The aim of the study was to investigate whether SIN-1, the active metabolite of molsidomine, develops a direct myocardial anti-ischemic property. Three groups of seven patients each were treated with 0.4 mg SIN-1 administered via either the intracoronary (IC) or intravenous (IV) route, or with placebo in a double-blind randomized investigation. SIN-1 had no influence on either the ischemic parameters in the surface electrocardiogram (ECG) or the intracoronary ECG. There was also no change in peripheral or central hemodynamics or in the severity of angina following this low IC or IV dosage. There is no evidence of a direct myocardial anti-ischemic response of SIN-1. The well known anti-ischemic activity of SIN-1 or molsidomine has to be attributed to the proven peripheral and cardiac vascular responses.
No takes yet. Share an insight, caveat, or question.
Kober et al. (1993) conducted an RCT in Ischemia / Angina (n=21). SIN-1 vs. Placebo was evaluated on Ischemic parameters in surface and intracoronary ECG. SIN-1 had no influence on ischemic parameters in ECG, hemodynamics, or angina severity compared to placebo, showing no direct myocardial anti-ischemic response.
Synapse has enriched 10 related papers. Consider them for comparative context: